Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Abbott Laboratories (NYSE:ABT) both recently posted earnings that show two healthcare giants moving in opposite strategic directions.

JNJ is tightening its focus by spinning off Orthopaedics, while Abbott just closed a $21 billion Exact Sciences deal. The businesses behind these tickers look nothing alike right now.

Oncology Powers JNJ. Cancer Diagnostics Reshapes Abbott.

JNJ’s Q1 report leaned on its Innovative Medicine engine, with segment revenue of $15.43 billion, up 11.2%. DARZALEX brought in $3.96 billion (+22.5%), TREMFYA jumped 68.3%, and CARVYKTI kept scaling. That momentum is doing heavy lifting because STELARA collapsed 59.7% against biosimilars, a real drag that TREMFYA is fortunately absorbing.

Abbott’s Q2 story is different. Medical Devices delivered $5.85 billion, up 9%, led by FreeStyle Libre continuous glucose monitors at $2.19 billion. Diagnostics surged 42.3% almost entirely because Cologuard from Exact Sciences contributed $919 million. Strip that out and comparable sales grew a more modest 4.8%, which is less flashy but more representative.

CEO Joaquin Duato framed JNJ’s quarter as “a strong start to 2026”, citing approvals for ICOTYDE and VARIPULSE Pro. Abbott CEO Robert Ford was more forward-looking, saying results “reflect the momentum we are building” heading into H2. 

Narrowing the Portfolio vs. Widening the Net

JNJ is pruning. Abbott is stacking.

JNJ raised full-year revenue guidance to $100.3B to $101.3B and adjusted EPS to $11.45 to $11.65. Abbott lifted its EPS range to $5.45 to $5.60, though acquisition financing pushed interest expense to $299 million from $50 million. Digesting that debt is real work.

The Next Test Is Execution

For JNJ, I want to see whether TREMFYA and DARZALEX can keep outpacing the STELARA cliff, and whether the DePuy Synthes separation stays on schedule.

For Abbott, the Cologuard integration needs to produce durable margin expansion beyond the optical revenue lift. Nutrition remains a soft spot at down 3.1%, and Structural Heart U.S. slid 9.8%. Both issues are manageable but deserve close attention.

The stocks themselves have diverged sharply. JNJ is up 23.63% year to date, while Abbott is down 18.16%. That gap has already priced in a lot of the narrative.

Why I Lean JNJ Today, but Watch Abbott Closely

If you want stability, JNJ looks like the cleaner story to me right now. Oncology is compounding, the pipeline delivered multiple game-changing approvals this quarter, and the 64th consecutive year of dividend increases speaks to durability. The 2.1% yield is modest, but reliable.

That said, I think Abbott is the more interesting turnaround setup. Shares trade cheaper on forward earnings, the yield is higher at 2.51%, and if Cologuard integration delivers, sentiment could snap back quickly.

Abbott is unlikely to offer a smooth ride over the next two quarters, but for investors comfortable with post-acquisition messiness, the risk-reward profile looks fairer than the YTD chart suggests. On balance, JNJ screens as the ballast name here, with Abbott worth monitoring closely.

Contact [email protected] for any questions or corrections.